392 related articles for article (PubMed ID: 15175944)
1. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
3. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
4. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
6. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
7. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.
Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G
Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937
[TBL] [Abstract][Full Text] [Related]
8. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
[TBL] [Abstract][Full Text] [Related]
10. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
[TBL] [Abstract][Full Text] [Related]
14. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
15. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Soga K; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
[TBL] [Abstract][Full Text] [Related]
16. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.
Larghi A; Tagger A; Crosignani A; Ribero ML; Bruno S; Portera G; Battezzati PM; Maggioni M; Fasola M; Zuin M; Podda M
J Med Virol; 1998 May; 55(1):7-11. PubMed ID: 9580879
[TBL] [Abstract][Full Text] [Related]
18. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.
Bernardinello E; Cavalletto L; Chemello L; Mezzocolli I; Donada C; Benvegnú L; Merkel C; Gatta A; Alberti A
Hepatogastroenterology; 1999; 46(30):3216-22. PubMed ID: 10626189
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
